Ossi Haapaniemi

Sinaptica Therapeutics™ is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The company’s SinaptiStim™ System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation based on unprecedented published Phase 2 sham-controlled data that achieved statistical significance on all four gold-standard cognitive & functional clinical endpoints. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and noninvasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on highly significant published sham-controlled data, the companys neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimer’s patients in over two decades, and is protected by multiple pending patents.

Sinaptica Therapeutics™ is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The company’s SinaptiStim™ System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation based on unprecedented published Phase 2 sham-controlled data that achieved statistical significance on all four gold-standard cognitive & functional clinical endpoints. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and noninvasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on highly significant published sham-controlled data, the companys neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimer’s patients in over two decades, and is protected by multiple pending patents.

Roschier is one of the leading law firms in the Nordic region with offices in Helsinki and Stockholm. The firm is well-known for its excellent track record of advising on demanding international business law assignments and large-scale transactions. The firm’s clients include leading domestic and international corporations, financial service and insurance institutions, investors, growth and other private companies with international operations, as well as governmental authorities. In total, Roschier currently employs some 525 staff members of which approximately 300 are lawyers/practitioners (some 170 located in Finland and some 130 in Sweden). Roschier is the exclusive member firm in Finland for Lex Mundi - the worlds leading network of independent law firms with in-depth experience in 100+ countries worldwide. For job openings and for more information on Roschier, please visit our website at www.roschier.com. Roschier - Your law firm when it matters.

Hannes Snellman is a leading Finnish business law firm entrusted by its clients in matters of critical importance. We are visionary, dedicated, and human — a team of outstanding professionals who work together in a collaborative and empowering environment. OUR SERVICES Administrative Proceedings Capital Markets Competition & Procurement Corporate Advisory Corporate Responsibility & Compliance Dispute Resolution Employment Environment & Natural Resources Finance Infrastructure & Energy Intellectual Property Joint Ventures & Commercial Cooperation Private Equity Private M&A Public M&A Projects & Construction Real Estate Restructuring & Insolvency Tax Technology

Evli on pohjoismainen varainhoitaja, joka auttaa yhteisöjä, yrityksiä ja yksityishenkilöitä kohti vauraampaa huomista. Tarjoamme palkittua ja tuloksellista varainhoitoa sekä laajan valikoiman erilaisia sijoitusratkaisuja 40 vuoden kokemuksella. Evlissä työskentelee 300 ammattilaista ja hallinnoimme 19,0 miljardin euron asiakasvarallisuutta (netto 3/2025). Evlin B-sarjan osakkeet on listattu Helsingin pörssiin.